Cancer Vaccine
Combination Vaccine for Neuroblastoma
Recruiting1 awardPhase 1 & 2
Houston, Texas
This trial tests a new treatment for high-risk neuroblastoma using two types of cancer cell vaccines. One vaccine is modified to release proteins that boost the immune system. The goal is to help the body fight cancer more effectively.
Cell Therapy
Immunotherapy for Neuroblastoma
Recruiting2 awardsPhase 1
Los Angeles, California
This trial will determine how well autologous expanded natural killer cells work with standard dosing of dinutuximab and with or without lenalidomide in treating children with neuroblastoma that has come back or does not respond to treatment.
Alkylating agent
Sorafenib + Cyclophosphamide/Topotecan for Neuroblastoma
Recruiting3 awardsPhase 1
Los Angeles, California
This trial will test a combination of 3 drugs - sorafenib, cyclophosphamide, and topotecan - to see if it's effective and safe for patients with neuroblastoma that has resisted or returned after treatment.
Popular Filters
Trials for NBL Patients
Monoclonal Antibodies
Combination Therapy for Neuroblastoma
Recruiting1 awardPhase 2
Memphis, Tennessee
This trial is testing a new monoclonal antibody (mAb) to see if it is effective in treating neuroblastoma, a cancer that commonly affects children. The mAb targets a protein that is found on the surface of neuroblastoma cells.
CAR T-cell Therapy
CAR T-Cell Therapy for Neuroblastoma
Recruiting1 awardPhase 1
Houston, Texas
This trial involves treating patients with relapsed or refractory neuroblastoma using specially modified immune cells that can better recognize and attack their cancer. These modified cells are supported by chemotherapy and an additional drug to help them work more effectively. The goal is to see if this approach can safely extend the time these cells stay active in the body and improve their ability to fight cancer.
Cancer Vaccine
Tumor Cell Vaccine + Cytoxan for Neuroblastoma
Recruiting1 awardPhase 1 & 2
Houston, Texas
This trial is testing an experimental treatment for neuroblastoma, which is a solid tumor that is the second most common cancer in children. The treatment consists of a series of immunizations using a tumor vaccine, combined with low-dose chemotherapy taken by mouth on a daily basis. The hope is that the vaccine will cause the immune system to recognize and kill more types of neuroblastoma tumors. Additionally, the immunizations will be combined with daily low dose chemotherapy.
Cancer Vaccine
Vaccine + Immunological Adjuvant for Neuroblastoma
Recruiting1 awardPhase 1 & 2
New York, New York
This trial is testing a bivalent vaccine that has two antigens, GD2L and GD3L. The goal is to see if the patient's immune system can make antibodies against the two antigens, which would then attach to neuroblastoma cells and kill them.
Trials for Cancer Patients
Histone Deacetylase (HDAC) Inhibitor and PI3K Inhibitor
CUDC-907 for Pediatric Cancer
Recruiting1 awardPhase 1
San Francisco, California
This trial is testing a new drug called CUDC-907 to see if it can help children with certain cancers that haven't responded to other treatments. The drug works by blocking proteins that help cancer cells grow. The main goal is to find the safest dose for children and see if the drug has any benefits.
Peptide Receptor Radionuclide Therapy
Peptide Receptor Radionuclide Therapy for Neuroblastoma
Recruiting1 awardPhase 1 & 2
New York, New York
This trial is testing a new treatment called 67Cu-SARTATE for children with high-risk neuroblastoma. The treatment uses radiation to target and kill cancer cells. The goal is to see if this approach is safe and effective for these patients.
CAR T-cell Therapy
CAR T Cell Therapy for Pediatric Solid Cancers
Recruiting1 awardPhase 1
Seattle, Washington
This trial is testing genetically-modified T cells to treat solid tumors in children and young adults. The goal is to evaluate safety and feasibility, and to determine if the cells can kill tumors.
CAR T-cell Therapy
CAR T-Cell Therapy for Pediatric Cancer
Recruiting1 awardPhase 1
Memphis, Tennessee
This trial is for patients ≤ 21 years old with relapsed/refractory B7-H3+ solid tumors, investigating the use of autologous T cells genetically engineered to express B7-H3-CARs. The study will evaluate the safety and maximum tolerated dose of B7-H3-CAR T cells.
CAR T-cell Therapy
CAR T Cell Therapy for Pediatric Cancer
Recruiting1 awardPhase 1
Seattle, Washington
This trial tests a new treatment for children and young adults with hard-to-treat solid tumors. It uses the patient's own immune cells, modified to better attack cancer cells. The study aims to see if this approach is safe and effective. This type of therapy has shown remarkable results in young patients with certain types of blood cancers.
Trials for Metastatic Patients
CAR T-cell Therapy
CAR T-Cell Therapy for Neuroblastoma
Recruiting1 awardPhase 1
Houston, Texas
This trial involves treating patients with relapsed or refractory neuroblastoma using specially modified immune cells that can better recognize and attack their cancer. These modified cells are supported by chemotherapy and an additional drug to help them work more effectively. The goal is to see if this approach can safely extend the time these cells stay active in the body and improve their ability to fight cancer.
CAR T-cell Therapy
EBV-specific CTLs for Neuroblastoma
Recruiting1 awardPhase 1
Houston, Texas
This trial is testing a new way to fight neuroblastoma, a form of cancer, by combining two different types of cells that each attack the disease in different ways. The new cell is made by attaching an antibody that recognizes neuroblastoma cells to a type of cell that normally fights infectious mononucleosis. This new cell is given to patients with neuroblastoma that has returned and is not responding to other treatments.
Hu3F8 PET Imaging for Brain Cancer
Recruiting1 award
New York, New York
This trial is studying how a special protein called Hu3F8 moves through the body and targets tumors. Hu3F8 is designed to attach to tumor cells, helping the immune system recognize and destroy them. The study focuses on patients with tumors to see how well this protein works in attacking cancer cells.
Trials for MYC Positive Patients
Monoclonal Antibodies
Combination Therapy for Neuroblastoma
Recruiting1 awardPhase 2
Memphis, Tennessee
This trial is testing a new monoclonal antibody (mAb) to see if it is effective in treating neuroblastoma, a cancer that commonly affects children. The mAb targets a protein that is found on the surface of neuroblastoma cells.
Cancer Vaccine
Vaccine + Immunological Adjuvant for Neuroblastoma
Recruiting1 awardPhase 1 & 2
New York, New York
This trial is testing a bivalent vaccine that has two antigens, GD2L and GD3L. The goal is to see if the patient's immune system can make antibodies against the two antigens, which would then attach to neuroblastoma cells and kill them.
Hu3F8 PET Imaging for Brain Cancer
Recruiting1 award
New York, New York
This trial is studying how a special protein called Hu3F8 moves through the body and targets tumors. Hu3F8 is designed to attach to tumor cells, helping the immune system recognize and destroy them. The study focuses on patients with tumors to see how well this protein works in attacking cancer cells.
Trials With No Placebo
Monoclonal Antibodies
Combination Therapy for Neuroblastoma
Recruiting1 awardPhase 2
Memphis, Tennessee
This trial is testing a new monoclonal antibody (mAb) to see if it is effective in treating neuroblastoma, a cancer that commonly affects children. The mAb targets a protein that is found on the surface of neuroblastoma cells.
CAR T-cell Therapy
CAR T-Cell Therapy for Neuroblastoma
Recruiting1 awardPhase 1
Houston, Texas
This trial involves treating patients with relapsed or refractory neuroblastoma using specially modified immune cells that can better recognize and attack their cancer. These modified cells are supported by chemotherapy and an additional drug to help them work more effectively. The goal is to see if this approach can safely extend the time these cells stay active in the body and improve their ability to fight cancer.
Cancer Vaccine
Tumor Cell Vaccine + Cytoxan for Neuroblastoma
Recruiting1 awardPhase 1 & 2
Houston, Texas
This trial is testing an experimental treatment for neuroblastoma, which is a solid tumor that is the second most common cancer in children. The treatment consists of a series of immunizations using a tumor vaccine, combined with low-dose chemotherapy taken by mouth on a daily basis. The hope is that the vaccine will cause the immune system to recognize and kill more types of neuroblastoma tumors. Additionally, the immunizations will be combined with daily low dose chemotherapy.
Cancer Vaccine
Vaccine + Immunological Adjuvant for Neuroblastoma
Recruiting1 awardPhase 1 & 2
New York, New York
This trial is testing a bivalent vaccine that has two antigens, GD2L and GD3L. The goal is to see if the patient's immune system can make antibodies against the two antigens, which would then attach to neuroblastoma cells and kill them.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.